

# Jacob Y Shin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7927116/publications.pdf>

Version: 2024-02-01

28  
papers

1,780  
citations

706676

14  
h-index

563245

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2535  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes of dose-escalated hypofractionated external beam radiotherapy (5 Gy x 5 fractions) for spine metastasis. <i>Advances in Radiation Oncology</i> , 2022, 7, 100906.	0.6	1
2	Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, 115-117.	0.3	2
3	The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2018, 47, 1250-1257.	0.7	28
4	Locoregionally advanced oral cavity cancer: A propensity score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. <i>Head and Neck</i> , 2018, 40, 1934-1946.	0.9	3
5	Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer. <i>Lung</i> , 2018, 196, 351-358.	1.4	21
6	Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. <i>Journal of Clinical Neuroscience</i> , 2017, 37, 34-39.	0.8	10
7	External Validation of the New International Association for the Study of Lung Cancer Tumor, Node, and Metastasis 8th Edition Staging System and Updated T Descriptors in Determining Prognosis for Patients With Non-Small Cell Lung Cancer Patients With N3 Disease. <i>Clinical Lung Cancer</i> , 2017, 18, e481-e489.	1.1	7
8	Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. <i>Journal of Neuro-Oncology</i> , 2017, 132, 89-98.	1.4	8
9	Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation?. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 77-82.	0.8	9
10	Association of Insurance and Community-Level Socioeconomic Status With Treatment and Outcome of Squamous Cell Carcinoma of the Pharynx. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 899.	1.2	35
11	Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. <i>Journal of Neuro-Oncology</i> , 2016, 129, 557-565.	1.4	12
12	Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. <i>Journal of Neuro-Oncology</i> , 2016, 129, 567-575.	1.4	7
13	Optimizing efficiency and safety in a radiation oncology department through the use of ARIA 11 Visual Care Path. <i>Practical Radiation Oncology</i> , 2015, 5, 295-303.	1.1	10
14	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. <i>Gynecologic Oncology</i> , 2015, 136, 491-497.	0.6	58
15	The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients. <i>International Journal of Breast Cancer</i> , 2014, 2014, 1-14.	0.6	14
16	Factors associated with publication of plenary presentations at the Society of Gynecologic Oncologists annual meeting. <i>Gynecologic Oncology</i> , 2013, 128, 128-131.	0.6	7
17	Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. <i>Journal of Surgical Oncology</i> , 2008, 97, 103-107.	0.8	82
18	The influence of conservative surgical practices for malignant ovarian germ cell tumors. <i>Journal of Surgical Oncology</i> , 2008, 98, 111-116.	0.8	79

#	ARTICLE	IF	CITATIONS
19	Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. <i>Cancer</i> , 2008, 112, 820-830.	2.0	304
20	Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 95-99.	0.6	14
21	Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. <i>Gynecologic Oncology</i> , 2008, 109, 370-376.	0.6	359
22	Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1511-1518.	0.8	58
23	Vulvar Melanoma. <i>Obstetrics and Gynecology</i> , 2007, 110, 296-301.	1.2	125
24	Influence of the Gynecologic Oncologist on the Survival of Ovarian Cancer Patients. <i>Obstetrics and Gynecology</i> , 2007, 109, 1342-1350.	1.2	123
25	Adjuvant Radiotherapy in Incompletely Staged IC and II Endometrioid Uterine Cancer. <i>Obstetrics and Gynecology</i> , 2007, 110, 1237-1243.	1.2	11
26	Lymphadenectomy in endometrioid uterine cancer staging. <i>Cancer</i> , 2007, 109, 2454-2460.	2.0	85
27	Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—An analysis of 376 women. <i>Gynecologic Oncology</i> , 2007, 104, 396-400.	0.6	155
28	The outcomes of 27,063 women with unstaged endometrioid uterine cancer. <i>Gynecologic Oncology</i> , 2007, 106, 282-288.	0.6	153